Drug Trial Radar · NCT05979311
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
463
Actual
Start
Feb 21, 2024
Primary completion
Apr 15, 2026
Study completion Mar 26, 2027
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare safety, efficacy, participant reported outcomes and implementation outcomes of a fixed dose combination (FDC) of a two-drug regimen dolutegravir (DTG) plus lamivudine (3TC) and a three-drug regimen FDC of bictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF) in HIV-1 infected adult participants who have not previously received antiretroviral therapy.
Conditions
- HIV
- HIV Infections
Interventions
DolutegravirDrug
Dolutegravir will be administered once daily.
LamivudineDrug
Lamivudine will be administered once daily.
BictegravirDrug
Bictegravir will be administered once daily.
EmtricitabineDrug
Emtricitabine will be administered once daily.
Tenofovir alafenamideDrug
Tenofovir alafenamide will be administered once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with plasma HIV- Ribonucleic acid (RNA) less than (<)50 copies per milliliter (c/mL) as per snapshot algorithm at Week 48Time frame: Week 48
Locations
64 sites in 17 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina
GSK Investigational Site
Córdoba, Argentina
GSK Investigational Site
Antwerp, Belgium
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
Brussels, Brussels Capital, Belgium
GSK Investigational Site
Hvidovre, Denmark
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Montpellier, France
GSK Investigational Site
Nice, France
GSK Investigational Site
Nîmes, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Cologne, Germany
GSK Investigational Site
Hamburg, Germany
GSK Investigational Site
München, Germany
GSK Investigational Site
Frankfurt am Main, Hesse, Germany
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Thessaloniki, Greece
GSK Investigational Site
Dublin, Ireland
GSK Investigational Site
Dublin, Ireland
GSK Investigational Site
Haifa, Israel
GSK Investigational Site
Ramat Gan, Israel
GSK Investigational Site
Rehovot, Israel
GSK Investigational Site
Tel Aviv, Israel
GSK Investigational Site
Bari, Italy
GSK Investigational Site
Bergamo, Italy
GSK Investigational Site
Padova, Italy
GSK Investigational Site
Pavia, Italy
GSK Investigational Site
Sassari, Italy
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Mérida, Mexico
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.